The WHO predicts hearing loss will impact 1 in 10 people by 2050. Medical devices are the standard of care, but they are ineffective for many people.

Despite a prevalence greater than cancer or diabetes, there are currently no treatments available to treat the underlying cellular dysfunction which is the root cause of hearing loss.

Lipid nanoparticle-based mRNA therapeutics were spectacularly validated as a mass market medicine through the COVID-19 pandemic. We believe the time is now to create the world’s first mass market medicine for hearing loss.

CamGene Therapeutics

Org chart

Teams

Offices